Ceftizoxime
Mechanism :
The bactericidal action of ceftizoxime results from inhibition of cell-wall synthesis. Cefizox is highly resistant to a broad spectrum of beta-lactamases. It is active against Klebsiella; Proteus mirabilis; Escherichia coli; Haemophilus influenzae including ampicillin-resistant strains; Staphylococcus aureus (penicillinase- and non-penicillinase-producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae.
Indication :
- Lower respiratory tract infections
- Urinary tract infections
- Intra-abdominal infections
- Septicemia
- Skin and soft tissue infections
- Bone and joint infections
Contraindications :
Documented hypersensitivity.
Dosing :
Neonates (off-label):
25-50 mg/kg IV every 12 hours.
<6 months old (off-label):
100-200 mg/kg/day IV divided every 8 hourly.
>6 months old:
150-200 mg/kg/day IV divided every 6-8 hourly; maximum dose: 12 g/day.
Adverse Effect :
Fever, pruritus, skin rash, leukopenia, thrombocytopenia, rise in liver enzymes and blood urea.
Interaction :
Live vaccines: Decrease the effect of the vaccines by pharmacodynamic synergism.
Hepatic Dose :
No dosage adjustments are recommended.